TGA grants provisional determination to Moderna’s COVID-19 bivalent (Original plus Omicron BA.4/BA.5) booster dose vaccine


30 September 2022 - On 28 September 2022, the TGA granted a provisional determination to Moderna's bivalent COVID-19 vaccine candidate: elasomeran and davesomeran (Spikevax Bivalent Original/Omicron BA.4/BA.5). 

The vaccine comprises mRNA for both the original and Omicron BA.4/5 strains and is for proposed use as a booster for active immunisation to prevent COVID-19.

Read TGA News

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Australia , Vaccine , COVID-19